Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer

Christine M. Bestvinaa University of Chicago Comprehensive Cancer Center; Department of Medicine, The University of Chicago, Chicago, IL, USA

Dexter Watersb Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA

Laura Morrisonc Analysis Group, Inc., Montréal, QC, CanadaCorrespondence[email protected]

Bruno Emondc Analysis Group, Inc., Montréal, QC, Canada

Marie-Hélène Lafeuillec Analysis Group, Inc., Montréal, QC, Canada

Annalise Hiltsc Analysis Group, Inc., Montréal, QC, Canada

Patrick Lefebvrec Analysis Group, Inc., Montréal, QC, Canada

Andy Heb Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA

Julie Vanderpoelb Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA

Your download is now in progress and you may close this window